单一景观空间分布指数及其适用性评价

为描述单一景观的空间分布离散性和广度特征,引入基于香农熵的空间分布指数(MSHDI,Modified Shannon's Distribution Index),利用河南省中南部地区1990、2001和2007年3期TM/ETM+遥感影像,进行了MSHDI与经典景观指数的比较,并分析了MSHDI与面积指数(PLAND,Percentage of Landscape)在多网格尺度下的相关关系。结果表明:(1)MSHDI在描述单一景观的空间分布广度和离散程度特征方面具有较好的适用性。MSHDI能适应不同制图综合程度的影响,并能反映出景观斑块边缘的细微差别。(2)通过分析MSHDI与PLAND之间相关系数的大小和变化程度可以分别验证MSHDI的表征性和稳定性。(3)MSHDI适用于基底和散布状景观,两种指数之间有显著的正相关性(农用地=0.939,=0.000;城市建设=0.877,=0.004;工矿仓储=0.870,=0.002;自然绿地=0.966,=0.001),且随网格粒度变化不大(农用地r=0.921±0.054;城市建设r=0.867±0.107;工矿仓储r=0.883±0.052;自然绿地r=0.964±0.024);而对网状景观则缺乏稳定性。     

卫星土壤水分产品在青藏高原地区的适用性评价

为了分析土壤水分产品在青藏高原地区的可靠性和适用性,利用青藏高原地区地下5 cm深度的地面实测土壤水分数据,结合多种评价指标（相关系数R、均方根误差RMSE、偏差Bias和无偏均方根误差ubRMSE）对土壤水分主动-被动探测卫星（SMAP）、高级微波扫描辐射计2（AMSR2）、风云三号（FY-3B）土壤水分产品,从时间和空间两个方面进行了适用性研究。结果表明：（1）土壤水分产品均能反映青藏高原的土壤水分变化,在降水较多的季节,三种产品精度均有不同程度的下降。（2）土壤水分产品在夏季和秋季反演效果好于冬季和春季,并且在秋季与实测值更接近。其中,SMAP产品在各个区域都能反映土壤水分的季节变化趋势,并普遍在夏季高估、冬季低估;AMSR2产品在夏季低估,冬季明显高估;FY-3B产品在夏季普遍低估。（3）土壤水分产品在那曲和狮泉河地区反演结果较好,在那曲地区与实测值相关性最高;在玛曲地区表现出较大的不确定性,虽然相关系数较高,但RMSE和Bias同样较高,整体精度较差;SMAP产品在阿里地区满足目标精度。综合来看,SMAP产品在青藏高原地区反演结果较为稳定,受气候和环境的影响较小,具有相对较大的R和较小的RMSE和Bias。     

Tissue Aspiration and Inverse Finite Element Characterisation of Soft Tissues

In this work we examined the determination of soft tissue parameters via tissue aspiration experiments and inverse finite element characterisation. An aspiration tube was put against the target tissue. The deformation of the tissue inside the tube caused by weak suction was tracked with a video based system. A strain energy function was employed to model the elastic behaviour of soft tissue and viscoelasticity was accounted for by means of a quasi-linear viscoelastic formulation. Friction between the aspiration tube and the aspirated tissue was included in the model. Based on the assumed material model, an optimal set of material parameters was found, in order to best fit the experimental data obtained from ex-vivo experiments on pig kidney cortex. The inverse method resulted in robust determination of the unknown material parameters.     

缺氧预适应研究的进展与展望

缺氧预适应这一生物进化上的内源性细胞保护机制,可被机体、器官、组织和细胞的重复缺氧暴露所激发。缺氧预适应的效应已由对重复缺氧局部／原位器官组织的保护（局部／原位缺氧预适应）发展到既保护远隔的各种异位器官组织（远程／异位缺氧预适应）又抗御其它种种非缺氧性应激（交叉／多能缺氧预适应）。在现有进展的基础上,缺氧预适应研究以及其可操作性和可应用性将有更大的发展空间。     

Principles of nonlinear regression modeling

Summary Five principles govern the selection of nonlinear regression models for bacterial growth. Examples are given of the various ways in which researchers have approached the problems of nonlinear regression modeling together with some discussion of linear modeling.Reference to a brand or firm name does not constitute endorsement by the US Department of Agriculture over others of a similar nature not mentioned.     

深圳地区参考作物蒸散量计算方法适用性分析

根据深圳1998~2007日值气象资料,以4种方法计算参考作物蒸散量,并以FAO Penman-Monteith公式计算结果为标准,评价其他各公式在深圳的适用性。结果表明:Irmark-Allen公式的月平均参考作物蒸散量及年参考作物蒸散量与Penman-Monteith公式结果没有显著差异,与Hargreaves公式和Pristley-Taylor公式计算结果差异显著,Hargreaves最大,Pristley-Taylor最小;Irmark-Allen公式、Pristley-Taylor公式与Penman-Monteith公式的相关性较高,而Hargreaves相关性较低。Irmark-Allen法可作为深圳地区缺少相关气象资料条件下计算ET0较理想的替代方法。     

Current approaches in dendritic cell generation and future implications for cancer immunotherapy

The discovery of tumor-associated antigens, which are either selectively or preferentially expressed by tumors, together with an improved insight in dendritic cell biology illustrating their key function in the immune system, have provided a rationale to initiate dendritic cell-based cancer immunotherapy trials. Nevertheless, dendritic cell vaccination is in an early stage, as methods for preparing tumor antigen presenting dendritic cells and improving their immunostimulatory function are continuously being optimized. In addition, recent improvements in immunomonitoring have emphasized the need for careful design of this part of the trials. Still, valuable proofs-of-principle have been obtained, which favor the use of dendritic cells in subsequent, more standardized clinical trials. Here, we review the recent developments in clinical DC generation, antigen loading methods and immunomonitoring approaches for DC-based trials.